These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

687 related items for PubMed ID: 16485516

  • 1. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C, Ciliberti P, Graziosi M, Riva L.
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R.
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [Abstract] [Full Text] [Related]

  • 3. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
    Ferrari R, Pasanisi G, Notarstefano P, Campo G, Gardini E, Ceconi C.
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
    Brugts JJ, Ferrari R, Simoons ML.
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
    [Abstract] [Full Text] [Related]

  • 5. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G, Nicolosi GL, Chiariello M, Ferrari R, Remme P, Tavazzi L.
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [Abstract] [Full Text] [Related]

  • 6. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R, Papa K, Bernocchi P, Gimbatti OJ, Golcea SS, Bettini A, Ceconi C.
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [Abstract] [Full Text] [Related]

  • 7. [Remodeling with angiotensin-converting enzyme inhibitors: from GISSI to PREAMI].
    Nicolosi GL.
    Ital Heart J; 2005 Nov; 6 Suppl 7():33S-39S. PubMed ID: 16485515
    [Abstract] [Full Text] [Related]

  • 8. [The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases].
    Ferrari R, Ambrosio G, Chiariello M.
    Ital Heart J; 2005 Nov; 6 Suppl 7():3S-4S. PubMed ID: 16485511
    [No Abstract] [Full Text] [Related]

  • 9. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
    Gosse P.
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):319-33. PubMed ID: 16716093
    [Abstract] [Full Text] [Related]

  • 10. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials.
    Bertrand ME.
    Curr Med Res Opin; 2004 Oct; 20(10):1559-69. PubMed ID: 15462689
    [Abstract] [Full Text] [Related]

  • 11. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH.
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [Abstract] [Full Text] [Related]

  • 12. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
    Ferrari R, Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators.
    Arch Intern Med; 2006 Mar 27; 166(6):659-66. PubMed ID: 16567606
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C, Mastrorilli F, Squasi PA, Gaitani S, Guardigli G, Ferrari R.
    Ital Heart J; 2005 Nov 27; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
    Boos CJ.
    Med Sci Monit; 2004 Dec 27; 10(12):SR23-8. PubMed ID: 15567997
    [Abstract] [Full Text] [Related]

  • 15. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
    Dinicolantonio JJ, Lavie CJ, O'Keefe JH.
    Postgrad Med; 2013 Jul 27; 125(4):154-68. PubMed ID: 23933903
    [Abstract] [Full Text] [Related]

  • 16. Evidence for benefits of perindopril in hypertension and its complications.
    Laurent S.
    Am J Hypertens; 2005 Sep 27; 18(9 Pt 2):155S-162S. PubMed ID: 16125052
    [Abstract] [Full Text] [Related]

  • 17. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME, Remme WJ, Fox KM, Ferrari R, Simoons ML, EUROPA investigators.
    Int J Cardiol; 2007 Sep 14; 121(1):57-61. PubMed ID: 17270296
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety of antihypertensive therapy.
    Grossman E, Messerli FH.
    Prog Cardiovasc Dis; 2006 Sep 14; 49(1):16-25. PubMed ID: 16867847
    [Abstract] [Full Text] [Related]

  • 19. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.
    J Hypertens; 2008 Jul 14; 26(7):1282-9. PubMed ID: 18550998
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG.
    Arch Intern Med; 2006 Apr 10; 166(7):787-96. PubMed ID: 16606817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.